Label-Free Enrichment of Functional Cardiomyocytes Using Microfluidic Deterministic Lateral Flow Displacement by Zhang, Boyang et al.
Label-Free Enrichment of Functional Cardiomyocytes
Using Microfluidic Deterministic Lateral Flow
Displacement
Boyang Zhang
1,3, James V. Green
2, Shashi K. Murthy
2*, Milica Radisic
1,3*
1Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Ontario, Canada, 2Department of Chemical Engineering, Northeastern
University, Boston, Massachusetts. United States of America, 3Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada
Abstract
Progress in cardiac cell replacement therapies and tissue engineering critically depends on our ability to isolate functional
cardiomyocytes (CMs) from heterogeneous cell mixtures. Label-free enrichment of cardiomyocytes is desirable for future
clinical application of cell based products. Taking advantage of the physical properties of CMs, a microfluidic system was
designed to separate CMs from neonatal rat heart tissue digest based on size using the principles of deterministic lateral
displacement (DLD). For the first time, we demonstrate enrichment of functional CMs up to 9162.4% directly from the
digested heart tissue without any pre-treatment or labeling. Enriched cardiomyocytes remained viable after sorting and
formed contractile cardiac patches in 3-dimensional culture. The broad significance of this work lies in demonstrating
functional cell enrichment from the primary tissue digest leading directly to the creation of the engineered tissue.
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Introduction
There are nearly 16 million people in North America alone
suffering from coronary heart disease (CHD) with additional
770,000 new cases occurring annually contributing to $156 billion
in medical expenses and lost productivity per year [1]. The
majority of the cases involve at least one myocardial infarction
(MI) event. During MI, a regional blockage in the coronary
arteries constricts blood perfusion downstream which causes death
of cardiomyocytes (CMs) in the infarct zone. Depending on the
severity of infarction up to one billion CMs could be lost in the
infarct zone [2]. These cells cannot be readily replaced by the
heart since the adult mammalian CMs are considered to be
terminally differentiated, have extremely low proliferation rates [3]
and low turn-over rates in humans [4]. Instead, a non-contractile
scar forms that consists of fibroblasts and extracellular matrix.
Ultimately, a pathological remodeling process of the heart leads to
the thinning of the ventricular wall, dilatation of the ventricle and
diminishing ability of the heart to pump blood. Cell replacement
therapies offer the possibilities to develop new therapies for MI by
replacing CMs lost during an MI either through cell injection or
implantation of engineered cardiac patches.
Although non-myocyte cell types such as bone marrow cells
have been tested in clinical trials and demonstrated to exert
beneficial effects by improving vascularization and acting on the
myocardium through paracrine mechanisms and secretion of
growth factors [2,5–10] the replacement of contractile cells, CMs
is required for true regeneration. The first evidence that cell
injection may be a viable therapeutic approach for MI came from
rodent studies with injection of fetal or neonatal CMs. CM
injection improved left ventricular function and ventricle thick-
ness, thus attenuating pathological remodeling following MI [11–
14]. Injected CMs were demonstrated to integrate through gap
junctions and intercalated discs with the host CMs [15]. Our
group has worked extensively on growing patches of functional
cardiac tissue in vitro [16]. Cardiac tissue patches consisting of
scaffolds or hydrogels and primary rat CMs have been shown to
mediate cardiac function following myocardial infarction in rats
[17–18]. Recent advances in stem cell biology offer an unprec-
edented opportunity to generate millions of human CMs from
either embryonic stem cells (ESCs) [19] or induced pluripotent
stem cells (iPSCs) [20] to be used for cardiac cell therapy.
However, efficient cell separation methods are lacking. One of
the major challenges in growing functional tissues with defined cell
composition is the availability of purified cells [21]. It is generally
accepted that tri-culture of CMs, endothelial cells and fibroblasts
enhances engineered cardiac tissues in vitro [22,23] and enables
their survival in vivo [24,25]. However, providing defined tri-
culture requires first obtaining a homogenous cell population from
a heterogeneous cell source. Since all of the known CMs markers
are intracellular proteins, antibody staining (e.g. for cardiac
troponin I, [26]) or genetic labeling (e.g. neomycin resistance
under control of a myosin heavy chain promoter [27]) have so far
been used for identification of CMs and their separation. Antibody
staining of intracellular markers such as contractile proteins
requires cell permeabilization which unfortunately renders the
cells non-viable and unusable for cardiac therapy. On the other
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performed in humans due to ethical concerns.
Besides genetic manipulation, other characteristics of CMs have
also been explored as a basis for separation. Compared to other
cell types, CMs tend to contain more mitochondria in order to
sustain the energy requirement for contraction. Utilizing this
difference, Hattori et al. recently enriched CMs up to 99% purity
by labeling the mitochondria with a fluorescent marker, tetra-
methylrhodamine methyl ester perchlorate [28]. In addition, they
have shown that teratoma formation was prevented when
transplanting purified CMs into testes [28]. Furthermore, they
have also demonstrated that this method can be applied to cells
from various species including neonatal rats, mouse, and human
[28]. However, the long term effect of mitochondria labeling has
not been studied and cells whose intracellular components are
labeled with fluorescent probes are cannot be used in clinical
applications due to the unknown long-term effects of these organic
probe molecules in humans.
A new report identified SRP1a as a surface marker of CMs
derived from human pluripotent stem cells [29], but the wide
applicability of the SRP1a antibody across the species and the high
yield of CMs upon SRP1a labeling is yet to be determined.
Furthermore, use of mouse-raised antibodies for cell separation in
clinical applications can induce sensitization in patients and
generation of anti-mouse IgGs [30]. Therefore, bearing in mind
the complex health implication in future clinical studies, there is a
strong incentive for label-fee cell separation with minimal cell
treatment.
The most widely used label-free enrichment technique for CMs
derived from primary sources such as rat hearts is pre-plating [31].
This method makes use of the different cell attachment rate
between fibroblasts and CMs, where fibroblasts attach faster to the
tissue culture surface compared to the CMs. This non-specific
technique requires sequential plating steps each at ,1 hr/step that
are both time consuming and often lack consistency. For instance,
two rounds of pre-plating are required to enrich CMs to only 80%
[31]; further enrichment is not possible without significantly
undermining cell viability. Thus, presently, the high-purity, label-
free, separation of living CMs is virtually impossible. Therefore,
alternative properties of CMs must be explored.
It is well known that CMs, which specialize to generate
contractile force, occupy 80–90% of the heart volume due to their
large size compared to the other cells found in the heart [32].
Utilizing microfluidic technology, a diffusive filtering method
including one center channel and two side channels separated by
micro-sieves to block any large cells was introduced [33]. This
method was focused on the isolation of smaller non-myocytes and
cardiomyocytes were not be effectively enriched. In addition, this
device was prone to clogging by the larger cells and could not be
operated for longer periods of time. In 2004, Huang et al.
demonstrated a microfluidic post array system capable of
separating submicron particles in a continuous fashion without
clogging [34]. In laminar flow, such displacement can be predicted
and controlled which makes this method exceptionally sensitive
and consistent. This concept, termed deterministic lateral
displacement (DLD), was recently used for the separation of white
blood cells from red blood cells [35]. In addition, we previously
demonstrated this method for the separation of large mammalian
cells, such as H1975 epithelial cells from 3T3 fibroblasts [36]. In
this work, for the first time we custom-designed a separation array
based on the principle of DLD for the isolation of functional CMs
directly from primary cardiac tissue isolated from neonatal rats.
The sorted cells remained viable and were used for tissue
engineering of cardiac patches.
Results
Design of the sorting device
The layout of the device is shown in Figure 1(A). The
microfluidic device includes two sheath fluid inlets where
biological buffer, 3% (w/v) bovine serum albumin (BSA) in PBS
(phosphate buffered saline), was used to focus the cells into a
narrow stream. The cells focused by the sheath fluid flow through
the sorting chamber (5 cm in length and 1.3 cm in width) and are
collected in outlets 2–7 where outlet 2 is located in the middle of
the sorting chamber. As cells move through the sorting chamber,
large cells are expected to be displaced to the right side and
collected in Outlets 3–7 while smaller cells are expected to stay in
the middle of the chamber and collected in Outlet 2. The sorting
chamber is composed of an array of posts with diameter of 30 mm.
Each row of posts is slightly offset laterally from the previous row.
The extent of this offset determines the critical separation
diameter. Based on the cell size measurements discussed below,
we determined the critical separation diameter to be 7mm. The
exact device parameters to yield a critical separation diameter of
7.0 mm were determined based on the experimental correlation
published by Inglis [37]. The specific post arrangement param-
eters are shown in Table 1.
The critical separation diameter (Dc) depends on the offset of
the posts and the gap size between the posts. In addition, the
parabolic flow profile between adjacent posts also affects the
separation diameter. The governing equation is shown as eqn (1).
Dc~2gge ð1Þ
The shift factor is determined by the extent of offset by each row
of posts over the center-to-center distance between two adjacent
posts. The post gap is the distance between the edges of two
adjacent posts. Finally, the parabolic flow profile constant is a
correction factor that takes into account the parabolic velocity
profile between two adjacent posts. To further illustrate the
principle of the deterministic lateral displacement a FLUENT
hydrodynamic simulation of the fluid streamlines around the post
array was generated to demonstrate the splitting of the fluid
streams by the placement of the posts (Figure 1(A)). Intuitively, as
the offset (e) between each row of posts increases, the amount of
fluid getting diverted to the opposite side of the posts will be larger.
Therefore, the fluid streams will be able to carry and divert even
larger cells. This leads to an increase in critical separation
diameter as predicted in eqn (1). The gap size was chosen so that
the largest cells in the cell mixture can go through the post array
without clogging. This theory was explained with more details in
previous works [36].
Multiple external components were used to ensure proper
operation of the sorting device. First, to prevent cell settling inside
the syringe, a steel ball coated with PDMS and BSA was placed
inside the syringe and controlled by an external magnet to provide
agitation [38]. Without such agitation, cells would inevitably settle
inside the syringe resulting in decreased cell output over time.
Furthermore, due to their larger size and higher cell density, CMs
tend to settle faster in the syringe compared to non-myocytes
resulting in the reduced CMs purity from the syringe output in the
absence of agitation (Figure S1). Second, to prevent cells from
clumping inside the sorting chamber, a microfluidic filter
composed of a short array of posts with 20 mm gap was placed
upstream from the sorting device to filter out any cell clumps from
the tissue digestion allowing only single cells to move through the
system (Figure 1B). Lastly, a syringe pump was used to drive the
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pointing downward to prevent bubbles from the syringe entering
the device overtime.
To test the stability of the flow driven by the syringe pump at
the operating flow rate, red and blue color dyes were used to label
the cell solution and the sheath solution respectively. The flow rate
from the sheath inlet (500 mL/min) is nearly 6 times larger than
that from the cell inlet (80 mL/min), so that the cells can be
focused into a narrow stream that will only be collected by outlet 2.
Stable focusing is critical in ensuring high separation purity by
avoiding cross contamination. Figure 1(B) demonstrates the
stable hydrodynamic focusing at the center of the sorting chamber.
As expected red dye exited from the Outlet 2 only, demonstrating
that the focusing was stable throughout the sorting chamber. The
overall flow rate was chosen so that the Reynolds (Re) number at
the operating condition is below 1 (Re, 0.77), which is well within
the laminar flow regime where the principle of deterministic lateral
displacement can be applied.
Size distribution of primary cardiac cell mixture
To enrich CMs from digested heart tissue of neonatal rats based
on their size, the hydrodynamic diameter distribution of isolated
Figure 1. Device schematic and system setup. (A) The microfluidic sorting device is shown with the location of the inlets and outlets. Inset
represents a zoom-in section of the post array with FLUENT simulation of the fluid streamlines. An illustration of expected CMs purity from each
outlet is shown at the bottom. (B) An image of the system setup with color dyes illustrating stable hydrodynamic focusing. The blue dye is focused by
the red dyes into the center of the chamber and exits only from outlet #2. A 20 mm filter unit is placed upstream from the sorting chamber to
eliminate cell clumps.
doi:10.1371/journal.pone.0037619.g001
Table 1. Design Parameters of the Post Array.
Critical Separation Diameter
(Dc, mm) Shift Factor (e) Post Gap (g, mm) Parabolic Flow Profile Constant (g)
7.0 0.057 25 2.50
doi:10.1371/journal.pone.0037619.t001
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techniques such as measuring the size of suspended cells with
image analysis by outlining the perimeter of a cell from an image
may be inaccurate and lacks consideration of the volumetric shape
of the cells in 3-D. Here, a Coulter Counter was used to determine
the volume of the cell by measuring the electrical impedance
created by the cell passing through an aperture. The hydrody-
namic diameter of the cells was subsequently derived from the
volumetric measurement. The hydrodynamic diameter distribu-
tion of primary cardiac cell mixture in suspension is shown in
Figure 2(A). It is well known that this heterogeneous cell mixture
includes two major cell populations (fibroblasts 49% and CMs
47%) and other smaller populations (smooth muscle cells 3%,
endothelial cells 2%, and red blood cells) [39]. As Figure 2(A)
shows, there are indeed two major peaks: one around 5–6 mm and
another around 11–14 mm. The strong signals below 3 mm are
mostly due to system noise at the lower detection limit. The area
underneath the two major peaks was integrated to show that the
proportion of each peak (4–7 mm, 4565%, 7–20 mm, 5565%)
which corresponded with the reported proportion of CMs and
non-myocytes [39]. The percentages were further confirmed by
flow cytometry for cardiac Troponin T as described below. Since
there is no method available to isolate each type of cell without
permeating the cells, we were unable to determine the exact
diameter of each individual live cell type. The functionality of
Coulter Counter relies on non-permeated cell membranes given
that cell permeation would allow electrical current to pass through
the cell body and result in false measurement.
However, we hypothesized that the two peaks identified in
Figure 2(A) represent the two major cell populations, CMs and
non-myocytes (mostly fibroblasts) where the larger CMs were
located around the 11–14 mm peak while the smaller fibroblasts
were located around the 5–6 mm peak. Based on this hypothesis
the critical separation diameter was set at 7 mm. To confirm this
hypothesis, the cell mixture was first sorted based on the critical
separation diameter and subsequently identified with known
intracellular cardiac markers.
Cell population analysis
After examining the fraction of total cell input collected in each
outlet, it was clear that almost all the cells exited in Outlets 2–4
(Figure 2(B)). This indicates that the cells were displaced as far as
to Outlet 4 which corresponds to approximately 3 mm in lateral
displacement. Furthermore, since there were very few cells
collected from Outlet 1, this indicates that there was negligible
cell leakage into Outlet 1 which was designed to only collect the
sheath fluid. Additionally, the total number of cells collected in all
outlets of the device corresponded well to the total cell input (1
Million cells), indicating that the cell loss in the device was not
significant (Figure 2(B, inset)). Thus, our further analysis
focused on Outlets 2–4.
To confirm that separation was indeed based on size, the size
distribution of the cells collected from Outlets 2–4 was analyzed
with a Coulter Counter as shown in Figure 2(C). The fractions of
large cells (7–20 mm range) and small cells (4–7 mm) over the total
cell number from each Outlet were determined by integrating the
size distribution curve. Here, clear evidence of size dependent
separation between Outlets 2 and 3 was observed and the
separation diameter was ,7 mm as expected. Furthermore, the
size distribution appears to shift further to the larger end in Outlet
4 compared to Outlet 3. This demonstrates that the larger cells
tend to get displaced even further laterally, as expected. In Outlet
4, 9361% of the cells were large cells (7–20 mm) which indicates
significant enrichment of large cells compared to the control with
only 5565% large cells.
To analyze the CM purity in the outputs, an intracellular
marker, Troponin T, was used to identify the CMs by flow
cytometry after microfluidic separation. Propidium Iodide (PI)
staining was used to distinguish red blood cells from other non-
myocytes. As Figure 2(D, E) shows, before sorting the
heterogeneous cell population consisted of both Troponin T
positive CMs (60612%) and Troponin T negative non-myocytes
(40612%). After sorting, there was a clear trend of CMs
enrichment from Outlet 2 to Outlet 4, with Outlet 4 producing
the most enriched CMs population of 9162%. This value was
significantly higher compared to the control (cell mixture before
sorting) with p=0.01. The highest purity reached in the
experiments was 94%. The flow cytometry data were also
compared with the Coulter Counter data to show that the fraction
of cardiomyocytes determined from the flow cytometry data
closely resemble the fraction of large cells (7–20 mm) determined
from the Coulter Counter data (Figure 2D). The yield of this
separation process is 55% of the initial cardiomyocytes input. This
yield was determined by taking the ratio of the total number of
cardiomyocytes collected in outlet 4 to the total cardiomyocytes
input.
Functionality of enriched CMs
The effects of the sorting process on the viability and
functionality of the sorted cells were then characterized. First,
the cells collected from each outlet were stained with trypan blue
to characterize cell membrane integrity after sorting (Figure 3(A)).
There were no significant differences in viability between the
sorted cells and the control which were the unsorted cells
(Figure 3A). Furthermore there were no significant differences
between cells collected from each outlet (Figure 3(A)). Therefore,
cell viability and membrane integrity were not undermined by the
sorting process. Additional cell functionality tests were also
performed on enriched cardiomyocytes through 2D and 3D
culture.
The sorted cells were cultured on abraded surface to
demonstrate cell functionality in 2-D culture [40]. As shown in
Figure 3(C, D), sorted cells were able to exhibit normal
phenotypic responses such as elongation and cell alignment in
the direction of the abraded grooves. In addition, cross-striations
were visible in CMs upon Troponin T staining (Figure 3(C,
inset)). The sorted cells were also cultured in 3-D on scaffolds to
demonstrate their functionality in 3D and to characterize their
synchronized contraction after 3 days of cultivation; the sorted
cells connected and formed a synchronously beating cardiac patch.
The excitation threshold (ET) of the cardiac patch was
6.460.5 V/cm with a maximum capture rate of 5.361.5 pulses
per second consistent with previous work [41] (Figure 3(B)).
Engineered 2D and 3D tissue from enriched CMs were also
compared to those from pre-plate enriched cardiac cell mixture
(Figure 3 (C–F)). Qualitatively there was significant enrichment in
Troponin T positive CMs in the sorted CMs group compared to
the pre-plated control. However, as expected there were still few
non-myocytes mixed in with the CMs even in the sorted CMs
group. This could be contributed to the initial impurity from the
sorting process as well as further proliferation of non-myocytes
during culture period. CMs are a terminally differentiated cell type
and lack the ability to proliferate, therefore, overtime non-myocyte
proliferation will gradually undermine the initially high purity of
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37619Figure 2. Cell separation analysis. (A) Size distribution of primary cardiac cell mixture from digested heart tissue of neonatal rat (1–2 days old)
determined with Coulter Counter. Cell counts were normalized to the total number of cells counted. n=3 (B) Fraction of total cell input collected by each
outlet of the device. n=3. (B, inset) Comparison between the total number of cells collected and the total number of input cells. (C) Cell size distribution
fromeach outletofthe device. Cell countswerenormalized tothe total numberofcells counted. n=3 (D) CMs puritybeforeandafter sorting analysed by
Flow Cytometry. There is a significant difference between sorted cell population from Outlet 4 and cell population before sorting, p=0.01. n=3 (E)
Representative flow cytometry plots. Bluedotsrepresent Troponin T (+) cells. Red dots represent Troponin T (2) cells. PI staining is used to identify nuclei.
n=3.
doi:10.1371/journal.pone.0037619.g002
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Troponin T and connexin-43 indicated that the patches contained
elongated CMs (Figure 3(E), green) connected by punctuated
gap junctions (Figure 3(F), red).
Discussion
This work demonstrates the first enrichment of primary CMs
directly from a primary cell source, specifically heart tissue of
neonatal rats, to high purity levels without any labeling or pre-
treatment of the cells. In addition, a functional cardiac patch was
Figure 3. Viability and function of sorted cardiomyocytes. (A) Cell viability was measured by staining with trypan blue to confirm cell
membrane integrity after sorting. The number of trypan blue negative cells was counted against the total number of cells to get the fraction of live
cells. The control represents cell viability before sorting. (B) Excitation threshold and maximum capture rate measurement for cardiac patches
engineered from enriched CMs. (C) Sorted CMs and (D) CMs collected after pre-plating were cultured on abraded surfaces to demonstrate cell
alignment. Fluorescence image of Troponin T staining shows cell alignment and elongation in the direction of the grooves. Vimentin Staining labels
the nonmyocyte population (DAPI(blue), Troponin T(green), and Vimentin (red)). Cross striations indicated by arrow heads can also be observed. Black
arrow indicate the direction of the grooves. (E) Sorted CMs and (F) CMs collected after pre-plating were cultured on 3-D scaffold. Confocal images
shows the CMs population (Troponin T, green) and non-myocyte population (vimentin, red)(E, F) Confocal images of sorted CMs in 3-D scaffold to
show cell junction. (DAPI(blue), Troponin T(green), Connexin 43(red)).
doi:10.1371/journal.pone.0037619.g003
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of the enriched CMs after sorting and cultivation. This is a critical
step in engineering the next generation of complex cardiac tissues
with precise control over cell composition. The yield of current
device was determined to be around 55%. This low was caused
mostly by the lost of smaller cardiomyocytes in outlet 3. The yield
could potentially be improved with multiple runs by connecting
multiple sorting devices in series. However, the high throughput of
this system makes it possible to collect large amount of cells even at
lower yield as long as the input cell number is not limited. The
advantage of this microfluidic system is its ability to be scaled up
with parallel processing. Therefore, the total throughput and
processing time of this system is only limited by the extent of
multiplexing.
Currently, with this method a single device can consistently
enrich one million cells up to 9162% within 20 min. This
throughput is sufficient for cell culture studies, or for isolating
cardiomyocytes from cardiac biopsies for diagnostic applications.
Since this system requires only an external pump, it can be scaled-
up easily to 100 devices to process up to 100 million cells within
20 min to meet large demand without significantly increasing the
overall cost. Therefore this method is superior compared to
conventional enrichment methods. Conventional label-free en-
richment methods like pre-plating depend on sequential plating to
improve purity. For instance, it takes up to two rounds of pre-
plating to enrich CMs up to 80% [31]. Each round of pre-plating
can last up to 75 min. Therefore, the entire process can take more
than two hours. During this time viability of the CMs (the non-
adherent cells) will be undermined. In fact, pre-plating is rarely
performed more than two times sequentially due to the long
incubation time that leads to a severe decline in viability.
Therefore, CM purity up to 90% cannot be achieved via pre-
plating.
Furthermore, our system requires no pre-treatment or pre-
labeling to the cells which makes it ideal for clinical applications or
potential integration with other microfluidic units. The described
microfluidic device can be made portable and implemented in the
operating room without the need for extensive cell manipulation
or transport to off-site laboratories for diagnostics. Currently at the
research stage, the sorting devices require few hours to fabricate
and the flow system requires less than one hour to setup. If
commercialized, the flow system and the sorting device can be
integrated into a single system and would require minimal
experience to operate and few minutes to setup. The sorting
device can be reusable if it is made of glass material. The device
may also be useful in label-free separation of skeletal myoblasts
from primary tissues. Using engineering principles to achieve high
throughput label-free separation of CMs will have a significant
impact even when the CMs surface markers are fully established as
expensive antibodies and the auxiliary equipment such as FACS
will not be required. The broad implication of this work is the
demonstration of high purity separation of functional cardiomy-
ocytes from digested tissue through label-free method leading
directly to engineered tissue.
Methods
Cardiac cell size distribution measurement
The hydrodynamic diameters of the cells were measured with a
Beckman Z2 Coulter Counter. The 100 mm aperture was used to
resolve particle size from 2 to 40 mm. The Coulter Counter
scanned each cell as it passed through the aperture and recorded
the electrical impedance created by the cells. This electrical signal
was then converted into actual hydrodynamic diameter and
plotted as a histogram. Prior to the experimental measurement,
the machine was calibrated with 15 mm beads.
Microfluidic device fabrication
Microfluidic device masters were fabricated via standard soft
lithography techniques as described previously [42]. A silicon
wafer was coated with SU-8 photoresist with a spin coater. The
mask was drawn using AutoCAD software and printed with high
resolution onto a transparency. With the mask in place, the SU-8
photoresist was exposed to 365 nm, 11 mW/cm
2 UV light using a
mask aligner (Q2001, Quintel Co., San Jose, CA). The unexposed
photoresist was removed with SU-8 developer. Silicone elastomer
[poly(dimethylsiloxane), PDMS] and curing agent (10:1 ratio) were
molded with the SU-8 masters at 75uC for 3 hr. Inlet and outlet
holes were punched with 22-gauge needles. The replicas were
plasma treated and bonded to a glass slide. Tygon tubing was press
fitted into the holes.
Experimental system setup
To prevent unspecific cell attachment during the experiment,
the device was incubated with 3% BSA in PBS at room
temperature for one hour prior to experiment. To prevent
intercellular binding, the primary cells were also suspended in
PBS with 3% BSA at a concentration of 0.33 million cells/mL. 3%
BSA in PBS was also used as the sheath fluid to match the viscosity
of the cells suspension. The flow rates of the sheath fluid and the
cell suspension were 500 mL/min and 80 mL/min respectively.
With this operating condition, the cell suspension stream was
focused into a narrow stream. The flow of both sheath fluid and
cell suspension was driven by an external syringe pump (Harvard
Apparatus). To prevent bubbles from entering the device, the
syringe pump was titled at 45 degree angle with the syringes
pointing downward. The experiment took 20 to 30 min. To
prevent cell settling inside the syringe during this period, a steel
ball coated with PDMS and BSA was incorporated inside the
syringe to generate agitation with an external magnet [38]. The
solution was agitated every 2 min for 5 s. To prevent cell clumps
from entering the sorting device, an on-chip filter was used. This
on-chip filter was composed of three rows of posts with diameter of
30 mm, height of 40 mm and gap size of 20 mm which is larger
than all the single cells but smaller than cell clumps, thus only
allowing suspended single cells to go through.
Fluid dynamic simulation
Fluid dynamic simulation of the fluid velocity profile was
generated with FLUENT 6.3.26. Briefly, a repeating section of the
post array was created in Gambit 2.4.6 in 3-D based on the device
geometric parameters. Then, the inlet and outlet boundary
conditions were estimated based on the experimental flow rates.
Other boundaries were set as no-slip walls. A mesh was then
generated with finer meshes near the walls and more coarse mesh
away from the wall. The file was then transferred to FLUENT for
simulation. The fluid density and viscosity were estimated based
on the properties of water at 25uC. The simulation was solved with
the built-in algorithm for continuous incompressible fluids. The
mesh was refined to include approximately 2 million tetrahedral
cells and convergence was reached at 10
27. The fluid streamlines
were then plotted against the device geometrical outline.
Heart cell isolation from neonatal rats
Neonatal rat heart tissue was digested as described using a
standard isolation protocol [43]. Briefly, neonatal (1–2 day old)
Sprague-Dawley rats were first euthanized. The hearts were
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(w/v) solution of trypsin (Sigma, Canada) in Ca
2+ and Mg
2+ free
Hank’s balanced salt solution (HBSS) (Gibco, Canada) overnight
at 4uC. Then, collagenase II (Worthington, USA 220 units/mL) in
HBSS was used to further digest the heart at 37uC in series of five
4–8 min digestions. Right after the collagenase digestion and
without pre-plating, the cells were filtered with 40 mm cell strainers
and then re-suspended in 3% BSA in PBS ready for experiments.
As a control cell population in 2D and 3D cell culture, the native
heart cell isolate was pre-plated for 1 hr in T75 flasks. The non-
adherent cells, enriched for CMs, were collected and cultivated as
described below.
Cardiomyocyte culture medium
The CMs were cultured in Dulbecco’s Modified Eagle Medium
(DMEM, Gibco, Canada) containing 4.5 g/L glucose, with 10%
(v/v) fetal bovine serum (FBS, Gibco, Canada), 1% HEPES
(100 units/mL, Gibco Canada) and penicillin-streptomycin
(100 mg/mL, Gibco, Canada).
Cell population analysis
Cell concentrations were measured with a hemacytometer. Cell
collected from each outlet were first resuspended in PBS. Then the
cell concentrations were measured with a hemacytometer. The
total number of cell collected by each outlet was then determined
by multiplying the cell concentration with the suspension volume
(1 mL). The fraction of total input cells collected by each outlet
were then determined and compared with the total input cell
number (1 million cells) to examine the cell number loss within the
sorting device. To determine the percentage of CMs before and
after sorting, flow cytometry was used. For flow cytometry analysis,
the cells were fixed in 4% (w/v) solution of paraformaldehyde in
PBS for 15 min at room temperature and then permeated on ice
with cold methanol for 2 min.
Next, the cells were labeled with Troponin T (Mouse, clone 13–
11, Fisher Scientific) antibody for CM identification at dilution
ratio of 1:250 for 30 min on ice. Alexa 488 conjugated anti-mouse
IgG (Sigma), was then applied at dilution ratio of 1:200 for 30 min
on ice. Propidium Iodide (VWR) staining was performed at
concentration of 75 mg/mL. Stained cell suspensions were then
transported on ice to Princess Margaret Hospital for flow
cytometry analysis using BD FACS Calibur Flow Cytometer.
Immunostaining was performed to assess the phenotype of
cultured cells. The cells were first fixed in 4% (w/v) paraformal-
dehyde in PBS for 15 min at room temperature. Then, the cells
were permeated and blocked in 5% FBS and 0.25% Triton 6100
in PBS for 1 hour. Next, the sample was incubated in primary
antibody Troponin T (Mouse, clone 13–11, 1:200 dilution, Fisher
Scientific), anti-vimentin (Mouse, 1:200 dilution, sigma), and/or
Connexin 43 (Rabbit, 1:200 dilution, sigma) overnight at 4uC.
Followed by three washes, the samples were then incubated with
secondary antibodies, Alexa 488 conjugated anti-mouse IgG
(1:200 dilutions, Sigma) and/or TRITC conjugated anti-rabbit
IgG (1:200 dilution, Sigma) for 1 hour. The sample was then
imaged with a fluorescence microscope (Olympus IX2-UCB,
Canada) or a confocal microscope (Olympus FV5-PSU confocal
with IX70 microscope, Canada).
2D cell culture
To determine if the cells retain functionality following the
sorting, the sorted cells were seeded on polyvinyl surfaces with
isotropic abraded grooves [43,44]. Pre-plated cells served as
controls. The fabrication procedure of the abraded surface was
reported previously [44]. Briefly, the grooved surface was created
by repeatedly abrading a plastic slide uni-directionally with 400
grit super fine sand paper (Norton Premium). The abraded surface
was then cleaned with air gun and sonicated to eliminate residue
debris. Prior to cell seeding, the surface was sterilized with ethanol
and UV exposed overnight followed by coating with 0.2% Gelatin
(Type A from porcine skin, Sigma).
3D cell culture
To assess the ability of the sorted cells to form functional 3-
dimensional tissues, the sorted cells were seeded onto porous
collagen scaffold (3 mm diameter 6300 mm thick, Ultrafoam) at a
density of 10
8cells/cm
3 and cultured in cardiomyocyte medium.
Pre-plated cells served as controls. The culture medium was
replaced daily. On day 3, contractile properties were measured by
field stimulation in an electrical stimulation chamber consisting of
two parallel carbon electrodes spaced 1 cm apart as described
[45]. Stimulation was provided by an external electric stimulator
(Grass s88x). Using monophasic pulses of 2 ms duration and
frequency of 1 pulse per second, the excitation threshold
(minimum voltage at which synchronous contractions of 75% of
the tissue in the field of view can be observed) was first determined.
Then the maximum capture rate (maximum beating frequency)
was determined at 200% of the determined excitation threshold
voltage.
Statistical analysis
Error bars in figures represent standard deviation. Statistical
significance was determined using one-way ANOVA in conjunc-
tion with Tukey’s test. Normality and equality of variance were
tested. p,0.05 were considered significant. A minimum of 3
samples were used per data point.
Supporting Information
Figure S1 Analysis of cell output from syringes with and
without magnetic stirring.
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